The note from analyst Carol Werther comes after the PRIME study was selected as best abstract for the 34th Annual Dialysis Conference.
"This is the second time the PRIME data has been peer reviewed at a medical meeting. Triferic reduces ESA and IV iron use without increasing iron stores. In addition, the registrational CRUISE trials have demonstrated that Triferic is safe and effective in ESRD without increased iron stores. The most common reason patients have inadequate response to ESAs is decreased iron availability whether it is absolute or functional iron deficiency (FID). Hyporesponders cause considerable expense in both ESA and IV iron administration. In the bundled era, providers would benefit from using Triferic."
The stock is reaffirmed a Buy with $25 price target.